Sign in
Taking peopleNo phase

Evaluating Presbyopia-Correcting IOLs in Complex Cataract Cases With Anterior Segment Abnormalities

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
320 people, planned
Started
17 Nov 2025
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Unilateral Posterior Chamber Implantation of Presbyopia-Correcting IOL
  • Unilateral Posterior Chamber Implantation of Monofocal IOL
Record updated
7 January 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Lens Subluxation Unilateral Implantation Group; Patients aged 18-80 years with diagnosed lens subluxation meeting surgical indications for lens surgery, enrolled unilaterally; Informed consent for the study; Ability to comply with full follow-up; Kappa angle <0.5 mm, total higher-order aberration root mean square (HOA RMS) within the central 4-mm corneal zone <1 μm; Mesopic natural pupil diameter between 3.0 mm and 5.5 mm; Expected postoperative astigmatism ≤1.0 D, with target spherical equivalent between 0.00 D and ±0.75 D; Subjective desire to improve full-range visual function
  • Inactive Long-standing Anterior Uveitis with Cataract Unilateral Implantation Group; Patients aged 18-80 years with diagnosed inactive long-standing anterior uveitis (quiet for ≥3 months) and cataract meeting surgical indications for lens surgery, enrolled unilaterally; Centered pupil without significant deformity, with expected postoperative mesopic natural pupil diameter between 2.5 mm and 5.5 mm; Informed consent for the study; Ability to comply with full follow-up; Kappa angle <0.5 mm, total higher-order aberration root mean square (HOA RMS) within the central 4-mm corneal zone <1 μm; Expected postoperative astigmatism ≤1.0 D, with target spherical equivalent between 0.00 D and ±0.75 D; Subjective desire to improve full-range visual function
  • Post-myopic Laser Corneal Surgery with Cataract Unilateral Implantation Group; Patients aged 18-80 years with cataract following prior myopic laser corneal surgery meeting surgical indications for lens surgery, enrolled unilaterally; Informed consent for the study; Ability to comply with full follow-up; Kappa angle <0.5 mm, total higher-order aberration root mean square (HOA RMS) within the central 4-mm corneal zone <1 μm; Mesopic natural pupil diameter between 3.0 mm and 5.5 mm; Expected postoperative astigmatism ≤1.0 D, with target spherical equivalent between 0.00 D and ±0.75 D; Subjective desire to improve full-range visual function
  • Aphakia with Insufficient Residual Capsular Support Unilateral Implantation Group; Patients aged 18-80 years with aphakia and insufficient residual capsular support meeting surgical indications for IOL implantation, enrolled unilaterally; Informed consent for the study; Ability to comply with full follow-up; Kappa angle <0.5 mm, total higher-order aberration root mean square (HOA RMS) within the central 4-mm corneal zone <1 μm; Mesopic natural pupil diameter between 3.0 mm and 5.5 mm; Expected postoperative astigmatism ≤1.0 D, with target spherical equivalent between 0.00 D and ±0.75 D; Subjective desire to improve full-range visual function

Who cannot take part

  • Lens Subluxation Unilateral Implantation Group; Patients with coexisting ocular developmental anomalies such as microphthalmos or microcornea; Patients with severe or progressive ocular diseases (e.g., glaucoma, diabetic retinopathy, macular degeneration) or severe optic nerve disorders; Patients with other organic ocular pathologies, including pathologic high myopia with fundus changes, significant pupillary abnormalities (excessively large or small pupils), severe corneal disease or scarring, high irregular astigmatism, chronic uveitis, or severe amblyopia; Patients with lens disorders other than subluxation and cataract; Patients experiencing intraoperative complications that may affect IOL position and outcome (e.g., posterior capsule rupture, iris prolapse); Patients with a history of prior ocular surgery such as corneal refractive laser surgery, glaucoma surgery, or vitrectomy
  • Inactive Long-standing Anterior Uveitis with Cataract Unilateral Implantation Group; Patients with active systemic autoimmune diseases, or any systemic disease history or medication use known to significantly affect vision; Patients with coexisting ocular developmental anomalies such as microphthalmos or microcornea; Patients with severe or progressive ocular diseases (e.g., glaucoma, diabetic retinopathy, macular degeneration) or severe optic nerve disorders; Patients with other organic ocular pathologies, including pathologic high myopia with fundus changes, severe corneal disease or scarring, high irregular astigmatism, active uveitis, significant abnormalities of the lens capsule or zonules, or severe amblyopia; Patients experiencing intraoperative complications that may affect IOL position and outcome (e.g., posterior capsule rupture, iris prolapse); Patients with a history of prior ocular surgery such as corneal refractive laser surgery, glaucoma surgery, or vitrectomy
  • Post-myopic Laser Corneal Surgery with Cataract Unilateral Implantation Group; Patients with coexisting ocular developmental anomalies such as microphthalmos or microcornea; Patients with severe or progressive ocular diseases (e.g., glaucoma, diabetic retinopathy, macular degeneration) or severe optic nerve disorders; Patients with other organic ocular pathologies, including pathologic high myopia with fundus changes, significant pupillary abnormalities (excessively large or small pupils), severe corneal disease, high irregular astigmatism, chronic uveitis, significant abnormalities of the lens capsule or zonules, or severe amblyopia; Patients experiencing intraoperative complications that may affect IOL position or outcome (e.g., posterior capsule rupture, iris prolapse); Patients with a history of prior ocular surgery such as glaucoma surgery or vitrectomy
  • Aphakia with Insufficient Residual Capsular Support Unilateral Implantation Group; Patients with coexisting ocular developmental anomalies such as microphthalmos or microcornea; Patients with severe or progressive ocular diseases (e.g., glaucoma, diabetic retinopathy, macular degeneration) or severe optic nerve disorders; Patients with other organic ocular pathologies, including pathologic high myopia with fundus changes, significant pupillary abnormalities (excessively large or small pupils), severe corneal disease or scarring, high irregular astigmatism, chronic uveitis, or severe amblyopia; Patients experiencing intraoperative complications that may affect IOL position or outcome (e.g., iris prolapse); Patients with a history of prior ocular surgery such as corneal refractive laser surgery, glaucoma surgery, or posterior vitrectomy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of cataract surgery has evolved from simply restoring sight to providing clear and comfortable full-range vision. Traditionally, monofocal IOLs remain the routine choice for special cases with anterior segment abnormalities-such as lens subluxation, cataract with chronic uveitis, post-laser refractive cataract, and aphakia with insufficient capsular support. However, there is a growing demand among these patients for improved visual quality and spectacle independence.Currently, various presbyopia-correcting IOLs offer distinct advantages, providing more personalized options. The introduction and application of intraoperative optical coherence tomography (iOCT) ensures effective intraoperative monitoring. These advances make the precise implantation of presbyopia-correcting IOLs a promising extension to phacoemulsification in complex cataracts with anterior segment abnormalities.

Read full original descriptionShow less

Nevertheless, their exact benefits regarding visual quality, safety, and patient satisfaction require systematic evaluation through rigorous prospective studies and long-term follow-up. Under strict perioperative management, this study will employ iOCT to monitor the accurate implantation of presbyopia-correcting IOLs and will assess postoperative visual quality and patient satisfaction.

The 2 groups in the trial

  • Unilateral Posterior Chamber Presbyopia-Correcting IOL Implantation GroupTreatment being tested

    This arm includes four cohorts of cataract patients with different types of anterior segment structural abnormalities: the lens subluxation group, the chronic anterior uveitis with cataract group, the post-myopic laser corneal surgery with cataract group, and the aphakia with insufficient capsular support group. Patients in each group will undergo unilateral posterior chamber implantation of a suitable type of presbyopia-correcting IOL based on their individual characteristics.

    Treatment: Unilateral Posterior Chamber Implantation of Presbyopia-Correcting IOL

  • Unilateral Posterior Chamber Monofocal IOL Implantation GroupExisting treatment, for comparison

    This arm includes four cohorts of cataract patients with different types of anterior segment structural abnormalities: the lens subluxation group, the chronic anterior uveitis with cataract group, the post-myopic laser corneal surgery with cataract group, and the aphakia with insufficient capsular support group. Patients in each control group will undergo unilateral posterior chamber implantation of a monofocal IOL of the same brand as that used in the experimental group.

    Treatment: Unilateral Posterior Chamber Implantation of Monofocal IOL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study on the Application of Presbyopia-correcting Intraocular Lenses in the Surgery of Cataract Patients With Combined Anterior Segment Structural Abnormalities
Criteria questions
Built from NCT07321756, who can take part
Record updated
7 January 2026